B
Bernard Bayard
Researcher at Jean Monnet University
Publications - 61
Citations - 1772
Bernard Bayard is an academic researcher from Jean Monnet University. The author has contributed to research in topics: Barium ferrite & Ferrite (magnet). The author has an hindex of 15, co-authored 59 publications receiving 1720 citations. Previous affiliations of Bernard Bayard include Centre national de la recherche scientifique & University of Lyon.
Papers
More filters
PatentDOI
Oligonucleotides with modified phosphate and modified carbohydrate moieties at the respective chain termini
Bernard Lebleu,Bernard Bayard +1 more
TL;DR: The invention relates to novel oligonucleotides, the process for their preparation and their biological uses as mediators of the action of interferon, which have antiviral use.
Journal ArticleDOI
Specific antiviral activity of a poly(L-lysine)-conjugated oligodeoxyribonucleotide sequence complementary to vesicular stomatitis virus N protein mRNA initiation site.
TL;DR: The data suggest that oligonucleotide-poly(L-lysine) conjugates might become effective for studies on gene expression regulation and for antiviral chemotherapy.
Journal Article
State of the art about remote laboratories paradigms - foundations of ongoing mutations
TL;DR: This review explains why remote laboratories are at a technological crossroad, whereas they were slugging for a decade, and tries to identify possible evolutions for the next generation of remote laboratories.
Journal ArticleDOI
Activation of ribonuclease L by (2'-5')(A)4-poly(L-lysine) conjugates in intact cells.
TL;DR: Molecular hybrids synthesized by coupling (2'-5')(A)n oligoadenylates or 2-5A, an intracellular mediator involved in antiviral activity of interferons (IFNs), with poly(L-lysine) used as a membrane carrier promote transient inhibition of protein synthesis and a characteristic cleavage pattern of ribosomal RNAs in intact cells.
Journal ArticleDOI
Increased stability and antiviral activity of 2′‐O‐phosphoglyceryl derivatives of (2′‐5′)oligo(adenylate)
TL;DR: (2'-5')(A)n-PGro has a powerful antiviral activity against an RNA virus when microinjected with micropipettes into the cytoplasm of intact cells and remains transient however, possibly as a consequence of degradation in intact cells.